Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Polyrizon Ltd. (Nasdaq: PLRZ) Just Landed On The Krypton Street Watchlist This Morning—Monday, July 27, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At PLRZ While It’s Still Early This Morning… July 27, 2026 Dear Reader, This morning, PLRZ is Krypton Street's first name up on the screen. Last night we sent you the full setup. This morning the session opens with it. Polyrizon Ltd. (Nasdaq: PLRZ) moved approximately 17% in less than 24 hours the last time it was featured — tapping $15.80 on July 13 from the previous day's $13.40 range. That happened on a float under 1.5M shares. That structure is unchanged heading into today. Barchart's opinion tool is currently showing a perfect 13 out of 13 bullish signals — 100% bullish across all three timeframes simultaneously. If you read last night's update, you already know the story. If you have not, now is the time. The full breakdown is below. 
That kind of move on a float under 1.5M shares is not accidental. It is what happens when a tightly structured name starts getting the attention its setup deserves. Tonight, PLRZ is back at the top of the list — and this time, the technical picture is backing up everything the fundamentals already said. Barchart's technical analysis tool is currently showing a perfect 13 out of 13 bullish signals — 100% bullish across Short Term, Medium Term, and Long Term Indicators simultaneously. That kind of alignment across all three timeframes is rare. It does not guarantee what happens next. But when a name with the underlying structure of PLRZ shows up with a clean technical read like that heading into a Monday open, it deserves a second look. The story behind PLRZ has not changed. If anything, it has only moved closer to its next chapter. The Setup Has Not Moved — It Has Matured
What Krypton Street covered on July 14 remains fully intact. Nothing has been walked back. No timelines have shifted. The milestones that were in place two weeks ago are still in place — and patient enrollment is now two weeks closer. PLRZ entered this stretch with two major regulatory clearances behind it. On July 2, 2026, Polyrizon announced that NASARIX™ completed its full ISO 10993 biocompatibility program — every required biological safety test passed. Cytotoxicity. Sensitization. Irritation. Pyrogenicity. Acute systemic toxicity. The non-clinical safety package required before first-in-human testing is complete. Eleven days before that, BRANY Institutional Review Board approved the NASARIX™ clinical trial protocol — valid through June 17, 2027. Three major U.S. clinical sites are under contract. A European human nasal residence time study is active. The IP position is publishing in both the U.S. and Europe. The balance sheet $17.5M in cash, zero debt — has not changed. The first human trial has not started yet. That is where the story still sits — between a completed pre-trial foundation and the enrollment phase that follows. The gap between those two phases is now measured in weeks, not months. 100% Bullish Signals On Barchart
Technical tools are not a substitute for understanding the underlying story. But when a name with this kind of fundamental setup also presents a perfect 13/13 bullish reading on Barchart — covering Short Term, Medium Term, and Long Term Indicators simultaneously — it is worth noting for one simple reason: the technicals and the fundamentals are pointing the same direction at the same time. 100% bullish across all three timeframes is not something that shows up on every screen. It means the potential for momentum, and trend indicators are aligned in a way that does not happen on names moving sideways through a quiet period. Could something be building here—and did the fundamentals already explain why two weeks ago? Why the Float Still Matters
With fewer than 1.5M shares listed as available to the public, PLRZ’s small float could have the potential for big moves if demand begins to shift. When the July 13 move happened — approximately 17% in under 24 hours — it happened on that float. The same structure is still in place heading into Monday's session. That is not a coincidence. It is the structure. But the share structure is only part of the story, because the technology behind NASARIX™ may be the most important piece to understand. What NASARIX™ Is Actually Attempting
For context that matters going into Monday, here is the mechanistic point worth keeping in mind. The allergic rhinitis market is large, well-established, and still inadequate for a meaningful portion of sufferers. Antihistamines block the histamine receptor response — after allergen contact has already triggered the immune cascade. Corticosteroids reduce mucosal inflammation — also after the fact. Immunotherapy modifies the underlying immune response over years of treatment. None of them address the point of allergen entry. IMARC Group data shows the market continues expanding despite this — which reflects unmet need, not satisfaction. Healio's April 2026 reporting documented that pollen seasons in North America now start up to 20 days earlier than in the 1990s and last longer. The patient population requiring consistent therapy is growing, not stabilizing. NASARIX™ was built around a different mechanism entirely. A mucoadhesive hydrogel barrier applied to the nasal cavity that physically captures airborne allergens before they reach nasal epithelial tissue. No allergen contact means no immune cascade means no symptoms. That approach does not currently exist in the treatment landscape — and the medical device classification that governs it places PLRZ on a regulatory path that pharmaceutical competitors cannot simply replicate. That is the premise going into a first-in-human trial. The biocompatibility data says the device is safe for human tissue. The IRB says the protocol is ethically sound. The sites are ready. The capital is in place. What comes next is enrollment. The Milestones That Matter
July 2, 2026 — NASARIX™ Biocompatibility Program Complete 
Polyrizon announced that NASARIX™ passed its full ISO 10993 biocompatibility program — every required biological safety test cleared, including cytotoxicity, sensitization, irritation, material-mediated pyrogenicity, and acute systemic toxicity. The result satisfies the non-clinical safety requirement before first-in-human testing can begin. June 29, 2026 — Central IRB Approval Granted BRANY Institutional Review Board approved the NASARIX™ clinical trial protocol — confirming the study design, consent process, and patient protections meet applicable ethical standards for human research. The approval is valid through June 17, 2027, opening a defined 12-month window for site activation and patient enrollment. June 17, 2026 — U.S. Patent Publication for Trap & Target Platform 
Polyrizon received notice of U.S. patent publication for its Trap & Target mucoadhesive nasal delivery platform — extending IP coverage for the technology in one of the world's largest regulated markets. June 15, 2026 — European Human Performance Study Initiated Polyrizon announced a human nasal residence time study in collaboration with a leading European ENT medical center and a specialized CRO. The study is designed to characterize how long NASARIX™ maintains its barrier following application — data that will directly support the FDA regulatory submission. June 10, 2026 — European Patent Publication for Mucoadhesive Delivery Technology Polyrizon received notice of European patent publication for its mucoadhesive nasal delivery technology — complementing the U.S. publication and establishing IP protection for the Trap & Target platform across both major regulated markets simultaneously. June 8, 2026 — Three U.S. Clinical Sites Secured Polyrizon secured agreements with three major U.S. clinical sites for the NASARIX™ trial — the centers expected to generate the highest patient enrollment in the planned multi-center study. With site infrastructure in place before enrollment begins, the operational groundwork for the trial is ready. 7 Reasons Why We Have PLRZ Up On Our Screen Early This Morning—Monday, July 27, 2026…
1. 100% Bullish Technicals: Barchart's opinion tool is currently showing a perfect 13 out of 13 bullish signals across Short Term, Medium Term, and Long Term Indicators — the kind of technical alignment that rarely shows up without a reason behind it. 2. Recent Momentum: The last time PLRZ was featured on Krypton Street, it tapped $15.80 on July 13 — an approximate 17% move in less than 24 hours from the previous day's $13.40 range. 3. Float Under 1.5M Shares: With fewer than 1.5M shares in the public float, PLRZ has one of the tightest supply structures in its peer group — a factor that becomes increasingly relevant as the name approaches the enrollment phase. 4. Clinical Progress: PLRZ has completed key pre-trial milestones, including ISO 10993 biocompatibility testing, IRB approval, and agreements with three major U.S. clinical sites ahead of patient enrollment. 5. Strong Balance Sheet: PLRZ reported $17.5M in cash with zero debt, providing funding for its planned clinical development activities. 6. Patent Expansion: PLRZ has active U.S. and European patent publications covering its Trap & Target mucoadhesive nasal delivery platform while continuing to expand its intellectual property position. 7. Novel Approach: PLRZ is advancing NASARIX™, a mucoadhesive hydrogel barrier designed to physically capture airborne allergens before they reach nasal tissue, with patient enrollment for its first human trial drawing closer. Take A Look At PLRZ While It’s Still Early This Morning…
The fundamental picture has not changed. The milestones remain in place, the float is still extremely tight, and the clinical timeline continues moving forward. What has changed is the technical picture. For weeks, the underlying story has been building around the same core setup: fewer than 1.5M shares available to the public, an active development program, and a series of upcoming milestones that could keep PLRZ in focus. Now, the chart appears to be reinforcing what the fundamentals have already been showing. The last time PLRZ entered a similar setup, shares moved approximately 17% in under 24 hours. Heading into Monday, the same share structure remains in place, while the trial is now two weeks closer and several technical signals have strengthened. That does not guarantee what happens next, but it does explain why Krypton Street is paying especially close attention as the new week begins. Krypton Street has PLRZ at the top of its watchlist this morning. Take a look at PLRZ while it’s still early.
Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter |
